Canaccord lowered the firm’s price target on Alnylam to $283 from $284 and keeps a Buy rating on the shares. The firm saidthe big news from ots Q4 report was the changes to HELIOS-B’s statistical analysis plan affecting both primary/secondary endpoint structure and the trial’s duration. These changes delay the readout to late June/early July.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam initiated with a Peer Perform at Wolfe Research
- Alnylam price target lowered to $176 from $184 at Morgan Stanley
- Is ALNY a Buy, Before Earnings?
- Chardan lays out top 4 biotech picks for 2024
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com